Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

380.47 -10.98 (-2.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
 
Via Benzinga
Topics Stocks
This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside
Via Stocktwits
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
Earnings Scheduled For July 30, 2025
 
Via Benzinga
Top movers analysis in the middle of the day on 2025-09-02: top gainers and losers in today's session.
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics' Tyvaso showed significant lung function improvement in IPF patients, with plans to seek FDA approval for expanded use. 
Via Benzinga
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition. 
Via Investor's Business Daily
Tuesday's pre-market session: top gainers and losers
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
United Therapeutics Corp. (NASDAQ:UTHR) Embodies Peter Lynch's GARP Strategy
United Therapeutics (UTHR) exemplifies Peter Lynch's GARP strategy with strong EPS growth, zero debt, and an undervalued PEG ratio. A model for long-term investors. 
Via Chartmill
2 Mid-Cap Stocks with Competitive Advantages and 1 Facing Headwinds
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with... 
Via StockStory
3 Market-Beating Stocks to Consider Right Now
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
2 Profitable Stocks to Keep an Eye On and 1 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
1 Growth Stock to Stash and 2 Facing Challenges
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. 
Via StockStory
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Prime Value Investment with Strong Fundamentals and Undervalued Potential
UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech... 
Via Chartmill
UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per... 
Via StockStory
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It
The company is working through a patent battle that could seriously hamper sales of its new drug. 
Via Investor's Business Daily
Topics Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen
United Therapeutics Corp (UTHR) excels in the Caviar Cruise stock screen, showcasing strong revenue growth, high ROIC, robust cash flow, and a debt-free balance sheet—ideal for long-term investors. 
Via Chartmill
Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy
UNITED THERAPEUTICS CORP (UTHR) aligns with Peter Lynch's GARP strategy, boasting steady earnings growth (16.88% EPS), low PEG (0.70), zero debt, and strong profitability (17.31% ROE). A solid biotech... 
Via Chartmill
Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility
Joby Aviation (NYSE: JOBY) has recently experienced a significant surge in its stock value, fueled by a burgeoning "aviation buzz" surrounding the electric vertical takeoff and landing (eVTOL) aircraft... 
Via MarketMinute
Topics Economy Emissions
Forecasting The Future: 8 Analyst Projections For United Therapeutics
 
Via Benzinga
Earnings Summary on United Therapeutics
Via The Motley Fool
Topics Intellectual Property
United Therapeutics Stock Slides On Q2 Earnings: The Details
United Therapeutics Corp (NASDAQ:UTHR) reported second-quarter financial results before the market open on Wednesday. Here's a rundown of the report. 
Via Benzinga
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its GAAP profit of $6.41 per share... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.